ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) has received an average broker rating score of 1.67 (Buy) from the three brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and two have issued a strong buy recommendation on the company.

Analysts have set a one year consensus price target of $5.10 for the company, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 104 out of 265 based on the ratings given to related companies.

Several equities analysts have recently weighed in on EPIX shares. Zacks Investment Research upgraded ESSA Pharma from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research report on Monday, September 11th. Bloom Burton downgraded ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th.

ESSA Pharma (NASDAQ EPIX) traded down $0.01 during midday trading on Tuesday, hitting $0.24. The stock had a trading volume of 35,451 shares, compared to its average volume of 95,255. ESSA Pharma has a 1-year low of $0.24 and a 1-year high of $3.59. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of -3.00.

TRADEMARK VIOLATION NOTICE: “ESSA Pharma Inc. (EPIX) Given $5.10 Consensus Target Price by Analysts” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/essa-pharma-inc-epix-given-5-10-consensus-target-price-by-analysts.html.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.